July 2019
Volume 60, Issue 9
Open Access
ARVO Annual Meeting Abstract  |   July 2019
Lanosterol reverses the opacity of congenital cataract patient-specific-lentoid bodies derived from human iPSCs
Author Affiliations & Notes
  • Qiuli FU
    Eye Center, the 2nd Affiliated Hospital of Zhejiang University, Hangzhou, China
  • Danni Lyu
    Eye Center, the 2nd Affiliated Hospital of Zhejiang University, Hangzhou, China
  • Ke Yao
    Eye Center, the 2nd Affiliated Hospital of Zhejiang University, Hangzhou, China
  • Footnotes
    Commercial Relationships   Qiuli FU, None; Danni Lyu, None; Ke Yao, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science July 2019, Vol.60, 4295. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Qiuli FU, Danni Lyu, Ke Yao; Lanosterol reverses the opacity of congenital cataract patient-specific-lentoid bodies derived from human iPSCs. Invest. Ophthalmol. Vis. Sci. 2019;60(9):4295.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Recently, two research groups discovered that lanosterol and its derivatives had the ability to depolymerize the aggregated proteins and restored partial vision in animal models, which offers great hope in cataracts treatment using eye drops rather than surgery. However, whether lanosterol and its derivatives have similar effects on human cataracts as in animal models are still unclear. Our previous study established an efficient system-“fried egg” method in vitro for lentoid body (LB) generation from human pluripotent stem cells (PSCs), and found that LBs differentiated from congenital cataract (CC) patient specific iPSCs were cloudy which were consistent with the clinic symptoms of the patients (ARVO 2016, 2018). So, this study is to examine whether lanosterol could reverse the opacity of the patient-specific LBs.

Methods : Patient LBs were derived from CC patients’ iPSCs with β-crystallin,γ-crystallin and unknown mutations. Lanosterol were dissolved in DMSO in a concentration of 4 mM and diluted into 4 mM of working solution. The LB’s morphology was examined at certain time points. Representative images were taken using light microscopy and were used to evaluate the LBs’ degrees of transparency. Immunofluorescence staining was used to examine the expression patterns of crystallin. Representative pictures were used to quantify the number of protein aggregations.

Results : As the crystallin protein aggregations are the pathological foundation of cataracts, patients’ LBs were treated with lanosterol at D11 of differentiation process when the lens epithelial cells started to differentiate into lens fiber cells with massively increasing of crystalline expression. Our results showed that the percentage of transparent LBs on D21 were significantly higher in lanosterol treated conditions when compared to those without lanosterol treatment in three different types of LBs. Immunofluorescence examination showed that the number of crystallin aggregations was significantly decreased in patients’ LBs treated with lanosterol comparing to those without treatment, which was consistent with soluble/insoluble protein analysis.

Conclusions : Our results provide evidence that lanosterol is able to reverses the opacity of CC patient specific LBs, indicating the potential use of patient-specific LB platform in cataract drug screening.

This abstract was presented at the 2019 ARVO Annual Meeting, held in Vancouver, Canada, April 28 - May 2, 2019.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×